Published in J Am Geriatr Soc on December 10, 2008
Social Self-Management of Parkinson's Disease (SocM-PD) | NCT03938974
Validity of the MoCA and MMSE in the detection of MCI and dementia in Parkinson disease. Neurology (2009) 3.65
Conversion between mini-mental state examination, montreal cognitive assessment, and dementia rating scale-2 scores in Parkinson's disease. Mov Disord (2014) 2.30
MDS Task Force on mild cognitive impairment in Parkinson's disease: critical review of PD-MCI. Mov Disord (2011) 2.27
Olfactory dysfunction is associated with neuropsychiatric manifestations in Parkinson's disease. Mov Disord (2011) 1.57
Effects of Group, Individual, and Home Exercise in Persons With Parkinson Disease: A Randomized Clinical Trial. J Neurol Phys Ther (2015) 1.48
Association between cognition and function in patients with Parkinson disease with and without dementia. Mov Disord (2010) 1.37
Measuring cognition: the Chicago Cognitive Function Measure in the National Social Life, Health and Aging Project, Wave 2. J Gerontol B Psychol Sci Soc Sci (2014) 1.15
A recommended scale for cognitive screening in clinical trials of Parkinson's disease. Mov Disord (2010) 1.13
Genetic influences on cognitive decline in Parkinson's disease. Mov Disord (2012) 1.10
Parkinson's disease dementia: a neural networks perspective. Brain (2015) 1.10
Predictors of cognitive impairment in an early stage Parkinson's disease cohort. Mov Disord (2014) 0.98
Relationship between the Montreal Cognitive Assessment and Mini-mental State Examination for assessment of mild cognitive impairment in older adults. BMC Geriatr (2015) 0.96
Health-related quality of life in Parkinson disease: correlation between Health Utilities Index III and Unified Parkinson's Disease Rating Scale (UPDRS) in U.S. male veterans. Health Qual Life Outcomes (2010) 0.95
Parkinson's disease in women: a call for improved clinical studies and for comparative effectiveness research. Maturitas (2010) 0.93
Rapid cognitive screening of patients with substance use disorders. Exp Clin Psychopharmacol (2009) 0.92
Clinical heterogeneity in patients with early-stage Parkinson's disease: a cluster analysis. J Zhejiang Univ Sci B (2011) 0.91
Abnormal MoCA and normal range MMSE scores in Parkinson disease without dementia: cognitive and neurochemical correlates. Parkinsonism Relat Disord (2014) 0.89
Mood and cognition in leucine-rich repeat kinase 2 G2019S Parkinson's disease. Mov Disord (2011) 0.87
People with Parkinson's disease and normal MMSE score have a broad range of cognitive performance. Mov Disord (2014) 0.86
Validation studies of the Portuguese experimental version of the Montreal Cognitive Assessment (MoCA): confirmatory factor analysis. J Neurol (2009) 0.84
Cognitive performance on the mini-mental state examination and the montreal cognitive assessment across the healthy adult lifespan. Cogn Behav Neurol (2013) 0.84
Sleepiness in Idiopathic REM Sleep Behavior Disorder and Parkinson Disease. Sleep (2015) 0.84
Can we improve clinical prediction of at-risk older drivers? Accid Anal Prev (2013) 0.83
Emergence and evolution of social self-management of Parkinson's disease: study protocol for a 3-year prospective cohort study. BMC Neurol (2014) 0.80
Using the Montreal Cognitive Assessment Scale to screen for dementia in Chinese patients with Parkinson's Disease. Shanghai Arch Psychiatry (2013) 0.80
Utility of the NeuroTrax computerized battery for cognitive screening in Parkinson's disease: comparison with the MMSE and the MoCA. Int J Neurosci (2010) 0.80
Evidence for gender differences in cognition, emotion and quality of life in Parkinson's disease? Aging Dis (2013) 0.79
Screening Mild and Major Neurocognitive Disorders in Parkinson's Disease. Behav Neurol (2015) 0.79
Predictors of cognitive decline in the early stages of Parkinson's disease: a brief cognitive assessment longitudinal study. Parkinsons Dis (2013) 0.78
Effect of acupuncture treatment on vascular cognitive impairment without dementia: study protocol for a randomized controlled trial. Trials (2014) 0.78
Screening for Mild Cognitive Impairment in Parkinson's Disease: Comparison of the Italian Versions of Three Neuropsychological Tests. Parkinsons Dis (2015) 0.77
Changes of brain gray matter structure in Parkinson's disease patients with dementia. Neural Regen Res (2013) 0.77
Sexual dimorphism in Parkinson's disease: differences in clinical manifestations, quality of life and psychosocial functioning between males and females. Neuropsychiatr Dis Treat (2017) 0.77
Screening for DSM-IV-TR cognitive disorder NOS in Parkinson's disease using the Mattis Dementia Rating Scale. Int J Geriatr Psychiatry (2012) 0.76
Drivers with Parkinson's disease: are the symptoms of PD associated with restricted driving practices? J Neurol (2013) 0.76
Yizhi Xingnao prescription improves the cognitive function of patients after a transient ischemic attack. Neural Regen Res (2012) 0.76
Influence of aerobic exercise training on the neural correlates of motor learning in Parkinson's disease individuals. Neuroimage Clin (2016) 0.75
Nonmotor symptoms in primary adult-onset cervical dystonia and blepharospasm. Brain Behav (2016) 0.75
A randomized controlled trial of an enhanced interdisciplinary community based group program for people with Parkinson's disease: study rationale and protocol. Neurol Int (2012) 0.75
Neuropsychological profile in Chinese patients with Parkinson's disease and normal global cognition according to Mini-Mental State Examination Score. Int J Clin Exp Med (2015) 0.75
Hemispheric asymmetry of electroencephalography-based functional brain networks. Neuroreport (2014) 0.75
Differences in cognitive profiles between traumatic brain injury and stroke: A comparison of the Montreal Cognitive Assessment and Mini-Mental State Examination. Chin J Traumatol (2016) 0.75
Experiential and Doctrinal Religious Knowledge Categorization in Parkinson's Disease: Behavioral and Brain Correlates. Front Hum Neurosci (2016) 0.75
Screening for Cognitive Impairment in Parkinson's Disease: Improving the Diagnostic Utility of the MoCA through Subtest Weighting. PLoS One (2016) 0.75
Autonomy of patients with type 2 diabetes with an insulin pump device: is it predictable? J Diabetes Sci Technol (2014) 0.75
Unilateral ultra-brief pulse electroconvulsive therapy for depression in Parkinson's disease. Acta Neurol Scand (2016) 0.75
Side-of-onset of Parkinson's disease in relation to neuropsychological measures. Brain Behav (2016) 0.75
Reliability and Validity of the Beijing Version of the Montreal Cognitive Assessment in the Evaluation of Cognitive Function of Adult Patients with OSAHS. PLoS One (2015) 0.75
Correlation of sleep disturbance and cognitive impairment in patients with Parkinson's disease. J Mov Disord (2014) 0.75
Depression and social phobia in essential tremor and Parkinson's disease. Brain Behav (2017) 0.75
Using the Folstein Mini Mental State Exam (MMSE) to explore methodological issues in cognitive aging research. Eur J Ageing (2012) 0.75
"Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res (1975) 301.74
The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc (2005) 27.90
Population-based norms for the Mini-Mental State Examination by age and educational level. JAMA (1993) 12.83
Diagnostic criteria for Parkinson disease. Arch Neurol (1999) 11.65
Clinical diagnostic criteria for dementia associated with Parkinson's disease. Mov Disord (2007) 6.92
Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. Arch Neurol (2003) 4.76
Defining mild cognitive impairment in Parkinson's disease. Mov Disord (2007) 3.92
Evolution of cognitive dysfunction in an incident Parkinson's disease cohort. Brain (2007) 3.62
Cognitive profile of patients with newly diagnosed Parkinson disease. Neurology (2005) 3.29
Subtypes of mild cognitive impairment in Parkinson's disease: progression to dementia. Mov Disord (2006) 2.96
The cognitive ability of an incident cohort of Parkinson's patients in the UK. The CamPaIGN study. Brain (2003) 2.81
The meaning of cognitive impairment in the elderly. J Am Geriatr Soc (1985) 2.43
Test characteristics of the 15-item geriatric depression scale and Hamilton depression rating scale in Parkinson disease. Am J Geriatr Psychiatry (2006) 2.26
The Montreal cognitive assessment as a screening tool for cognitive impairment in Parkinson's disease. Mov Disord (2008) 2.15
A comparison of the mini mental state exam to the Montreal cognitive assessment in identifying cognitive deficits in Parkinson's disease. Mov Disord (2008) 1.98
Visual dysfunction in Parkinson disease without dementia. Neurology (2005) 1.67
Cognitive impairment in Parkinson's disease. J Neurol Neurosurg Psychiatry (2007) 1.59
Predictors of deterioration in health-related quality of life in Parkinson's disease: results from the DATATOP trial. Mov Disord (2008) 1.59
Memory and executive function impairment predict dementia in Parkinson's disease. Mov Disord (2002) 1.52
Neuropsychological profile of patients with Parkinson's disease without dementia. Dement Geriatr Cogn Disord (2003) 1.51
Assessment of cognition in Parkinson's disease. Neurology (2003) 1.45
Fluctuations in attention: PD dementia vs DLB with parkinsonism. Neurology (2002) 1.42
The detection of dementia and cognitive impairment in a community population of elderly people with Parkinson's disease by use of the CAMCOG neuropsychological test. Age Ageing (1999) 1.40
Dementia in Parkinson disease: a neuropsychological analysis. Brain Cogn (1982) 1.38
Cognitive assessment of a representative community population with Parkinson's disease (PD) using the Cambridge Cognitive Assessment-Revised (CAMCOG-R). Age Ageing (2005) 1.10
Medication use patterns among demented, cognitively impaired and cognitively intact community-dwelling elderly people. Age Ageing (1998) 1.07
Dementia and cognitive impairment in Parkinson's disease. J Neurol Neurosurg Psychiatry (1988) 1.02
Using the Mini-Mental State Examination for tracking cognition in the older population based on longitudinal data. J Am Geriatr Soc (2007) 0.95
A longitudinal study of neuropsychological change in individuals with Parkinson's disease. Int J Geriatr Psychiatry (2003) 0.84
Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. N Engl J Med (2006) 10.89
Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord (2008) 9.52
Bilateral deep brain stimulation vs best medical therapy for patients with advanced Parkinson disease: a randomized controlled trial. JAMA (2009) 8.40
Pallidal versus subthalamic deep-brain stimulation for Parkinson's disease. N Engl J Med (2010) 5.27
Frontotemporal dementia: clinicopathological correlations. Ann Neurol (2006) 5.14
Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines. Mov Disord (2012) 5.12
Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. Arch Neurol (2010) 4.77
Neuronal alpha-synucleinopathy with severe movement disorder in mice expressing A53T human alpha-synuclein. Neuron (2002) 4.77
Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Process, format, and clinimetric testing plan. Mov Disord (2007) 3.86
Plasma multianalyte profiling in mild cognitive impairment and Alzheimer disease. Neurology (2012) 3.58
Co-morbidity of TDP-43 proteinopathy in Lewy body related diseases. Acta Neuropathol (2007) 3.55
Randomized trial of deep brain stimulation for Parkinson disease: thirty-six-month outcomes. Neurology (2012) 3.46
Mitochondrial polymorphisms significantly reduce the risk of Parkinson disease. Am J Hum Genet (2003) 3.39
Cognitive impairment and PD patients' capacity to consent to research. Neurology (2013) 3.22
Biochemical and pathological characterization of Lrrk2. Ann Neurol (2006) 3.14
Association of dopamine agonist use with impulse control disorders in Parkinson disease. Arch Neurol (2006) 3.02
Facial emotion perception in schizophrenia: a meta-analytic review. Schizophr Bull (2009) 2.98
Identification of common variants influencing risk of the tauopathy progressive supranuclear palsy. Nat Genet (2011) 2.97
Age at onset in two common neurodegenerative diseases is genetically controlled. Am J Hum Genet (2002) 2.90
Dementia with Lewy bodies. Lancet Neurol (2004) 2.66
The scientific and clinical basis for the treatment of Parkinson disease (2009). Neurology (2009) 2.62
Depression rating scales in Parkinson's disease: critique and recommendations. Mov Disord (2007) 2.62
Neuropathological assessment of Parkinson's disease: refining the diagnostic criteria. Lancet Neurol (2009) 2.60
An odor-specific threshold deficit implicates abnormal intracellular cyclic AMP signaling in schizophrenia. Am J Psychiatry (2008) 2.53
A multicenter study of glucocerebrosidase mutations in dementia with Lewy bodies. JAMA Neurol (2013) 2.32
Conversion between mini-mental state examination, montreal cognitive assessment, and dementia rating scale-2 scores in Parkinson's disease. Mov Disord (2014) 2.30
Apathy and anhedonia rating scales in Parkinson's disease: critique and recommendations. Mov Disord (2008) 2.28
MDS Task Force on mild cognitive impairment in Parkinson's disease: critical review of PD-MCI. Mov Disord (2011) 2.27
Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial. Lancet Neurol (2010) 2.26
Test characteristics of the 15-item geriatric depression scale and Hamilton depression rating scale in Parkinson disease. Am J Geriatr Psychiatry (2006) 2.26
Plasma epidermal growth factor levels predict cognitive decline in Parkinson disease. Ann Neurol (2010) 2.20
Comparative accuracies of two common screening instruments for classification of Alzheimer's disease, mild cognitive impairment, and healthy aging. Alzheimers Dement (2012) 2.13
Novel CSF biomarkers for Alzheimer's disease and mild cognitive impairment. Acta Neuropathol (2010) 2.12
Neuropathologic substrates of Parkinson disease dementia. Ann Neurol (2012) 2.10
The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the non-motor symptoms of Parkinson's disease. Mov Disord (2011) 2.05
Parkin mutations and susceptibility alleles in late-onset Parkinson's disease. Ann Neurol (2003) 2.01
Effect of psychiatric and other nonmotor symptoms on disability in Parkinson's disease. J Am Geriatr Soc (2004) 2.00
Validation of the questionnaire for impulsive-compulsive disorders in Parkinson's disease. Mov Disord (2009) 1.89
Evaluation of alpha-synuclein immunohistochemical methods used by invited experts. Acta Neuropathol (2008) 1.81
An international consensus study of neuroleptic malignant syndrome diagnostic criteria using the Delphi method. J Clin Psychiatry (2011) 1.80
Amantadine use associated with impulse control disorders in Parkinson disease in cross-sectional study. Ann Neurol (2010) 1.77
Impulse control disorders in Parkinson disease: a multicenter case--control study. Ann Neurol (2011) 1.73
Recognition and treatment of depression in Parkinson's disease. J Geriatr Psychiatry Neurol (2003) 1.71
Lewy pathology is not the first sign of degeneration in vulnerable neurons in Parkinson disease. Neurology (2012) 1.69
Impaired olfaction and other prodromal features in the Parkinson At-Risk Syndrome Study. Mov Disord (2012) 1.60
Sertraline for the treatment of depression in Alzheimer disease. Am J Geriatr Psychiatry (2010) 1.60
Distinct antemortem profiles in patients with pathologically defined frontotemporal dementia. Arch Neurol (2007) 1.60
Olfactory dysfunction is associated with neuropsychiatric manifestations in Parkinson's disease. Mov Disord (2011) 1.57
The Penn Conditional Exclusion Test: a new measure of executive-function with alternate forms of repeat administration. Arch Clin Neuropsychol (2004) 1.57
Frequency of known mutations in early-onset Parkinson disease: implication for genetic counseling: the consortium on risk for early onset Parkinson disease study. Arch Neurol (2010) 1.56
Deep brain stimulation for movement disorders: morbidity and mortality in 109 patients. J Neurosurg (2003) 1.49
Mild cognitive impairment is common in Parkinson's disease patients with normal Mini-Mental State Examination (MMSE) scores. Parkinsonism Relat Disord (2008) 1.49
Probing the safety of medications in the frail elderly: evidence from a randomized clinical trial of sertraline and venlafaxine in depressed nursing home residents. J Clin Psychiatry (2003) 1.45
Patterns of cortical thickness associated with impulse control disorders in Parkinson's disease. Mov Disord (2015) 1.45
APOE ε4 increases risk for dementia in pure synucleinopathies. JAMA Neurol (2013) 1.41
Impulsive and compulsive behaviors in Parkinson's disease. Mov Disord (2009) 1.38
Predictors of parkin mutations in early-onset Parkinson disease: the consortium on risk for early-onset Parkinson disease study. Arch Neurol (2010) 1.38
Biomarker discovery for Alzheimer's disease, frontotemporal lobar degeneration, and Parkinson's disease. Acta Neuropathol (2010) 1.38
Association between cognition and function in patients with Parkinson disease with and without dementia. Mov Disord (2010) 1.37
Neuropsychological decline in frontotemporal lobar degeneration: a longitudinal analysis. Neuropsychology (2009) 1.35
Evidence for impaired encoding and retrieval memory profiles in Parkinson disease. Cogn Behav Neurol (2004) 1.34
Association of specialist involvement and quality of care for Parkinson's disease. Mov Disord (2007) 1.32
Antidepressant studies in Parkinson's disease: a review and meta-analysis. Mov Disord (2005) 1.32
Citalopram for agitation in Alzheimer's disease: design and methods. Alzheimers Dement (2012) 1.31
Neuropsychological deficits among patients with late-onset minor and major depression. Arch Clin Neuropsychol (2003) 1.30
Phosphorylated α-synuclein in Parkinson's disease. Sci Transl Med (2012) 1.29